Conjugated estrogens/medroxyprogesterone acetate
| Combination of | |
|---|---|
| Conjugated estrogens | Estrogen |
| Medroxyprogesterone acetate | Progestogen |
| Clinical data | |
| Trade names | Prempro, Premphase |
| Synonyms | CEs/MPA; CEEs/MPA |
| Routes of administration | By mouth |
| Drug class | Estrogen; Progestogen |
| Legal status | |
| Legal status |
|
Conjugated estrogens/medroxyprogesterone acetate (CEs/MPA), sold under the brand names Prempro and Premphase, is a combination product of conjugated estrogens (Premarin), an estrogen, and medroxyprogesterone acetate (Provera), a progestogen, which is used in menopausal hormone therapy for the treatment of menopausal symptoms.[1]
| Event | Relative Risk CEEs/MPA vs. placebo at 5.2 years (95% CI*) | Placebo (n = 8102) | CEEs/MPA (n = 8506) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Absolute Risk per 10,000 Women-Years | |||||||||
| Coronary heart disease events Non-fatal myocardial infarction Coronary heart disease death | 1.29 (1.02–1.63) 1.32 (1.02–1.72) 1.18 (0.70–1.97) | 30 23 6 | 37 30 7 | ||||||
| Invasive breast cancera | 1.26 (1.00–1.59) | 30 | 38 | ||||||
| Stroke | 1.41 (1.07–1.85) | 21 | 29 | ||||||
| Pulmonary embolism | 2.13 (1.39–3.25) | 8 | 16 | ||||||
| Colorectal cancer | 0.63 (0.43–0.92) | 16 | 10 | ||||||
| Endometrial cancer | 0.83 (0.47–1.47) | 6 | 5 | ||||||
| Hip fracture | 0.66 (0.45–0.98) | 15 | 10 | ||||||
| Death due to causes other than above | 0.92 (0.74–1.14) | 40 | 37 | ||||||
| Global Indexb | 1.15 (1.03–1.28) | 151 | 170 | ||||||
| Deep vein thrombosisc | 2.07 (1.49–2.87) | 13 | 26 | ||||||
| Vertebral fracturesc | 0.66 (0.44–0.98) | 15 | 9 | ||||||
| Other osteoporotic fracturesc | 0.77 (0.69–0.86) | 170 | 131 | ||||||
| WHI = Women's Health Initiative. CEEs = Conjugated estrogens. MPA = Medroxyprogesterone acetate. a = Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer. b = A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes. c = Not included in Global Index. * = Nominal confidence intervals unadjusted for multiple looks and multiple comparisons. Sources:[2][3] | |||||||||
See also
References
- ↑ MaryAnne Hochadel; Jerry Avorn (1 January 2007). The AARP Guide to Pills: Essential Information on More Than 1,200 Prescription and Nonprescription Medications, Including Generics. Sterling Publishing Company Incorporated. pp. 235–. ISBN 978-1-4027-4446-4.
- ↑ Warner Chilcott (March 2005). "ESTRACE TABLETS, (estradiol tablets, USP)" (PDF). fda.gov. Retrieved 27 November 2016.
- ↑ Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (July 2002). "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial". JAMA. 288 (3): 321–33. doi:10.1001/jama.288.3.321. PMID 12117397.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.